[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-gastritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-gastritis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100639619","phase-4-phase-4-study-of-sto-m-tab-in-acute-or-chronic-gastritis-100639619",false,"NCT07631065","Phase 4 Study of Sto M Tab. in Acute or Chronic Gastritis","A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Sto M Tab. in Patients With Acute or Chronic Gastritis","Inclusion Criteria:\n\n1. Male or female adults aged 19 to 75 years at the time of screening.\n2. Participants diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy performed within 7 days prior to randomization (Visit 2), with at least one gastric erosion confirmed. Erosions of the esophagus and duodenum are excluded.\n3. Female participants of childbearing potential or male participants who agree to maintain sexual abstinence or use appropriate contraceptive methods during the study period and for 2 weeks after the last administration of the investigational product. Periodic abstinence, such as calendar, ovulation, symptothermal, or post-ovulation methods, is not considered an acceptable contraceptive method.\n4. Participants who voluntarily provide written informed consent to participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Participants with any of the following lesions confirmed or accompanied by upper gastrointestinal endoscopy at screening (Visit 1): active or healing peptic ulcer; reflux esophagitis; Barrett's esophagus greater than 3 cm; gastroesophageal varices; esophageal stricture; or other clinically relevant lesions. Participants with ulcer scars may be enrolled.\n2. Participants who have a history of gastric acid secretion-inhibiting surgery or gastric or esophageal surgery at screening (Visit 1).\n3. Participants who have been diagnosed with or have a history of Zollinger-Ellison syndrome at screening (Visit 1).\n4. Participants with inflammatory bowel disease, such as Crohn's disease, ulcerative colitis, or intestinal Behcet's disease; primary esophageal motility disorder; or pancreatitis at screening (Visit 1).\n5. Participants with a history of malignancy within 5 years prior to screening (Visit 1). However, participants who have been completely treated and have had no recurrence for at least 5 years may be enrolled at the investigator's discretion. Participants with gastrointestinal malignancy are excluded regardless of the time since diagnosis. Participants with basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ of other sites may be enrolled at the investigator's discretion if they have been completely treated and have had no recurrence for at least 3 years.\n6. Participants with current or prior thrombotic disease at screening (Visit 1), such as cerebral thrombosis, myocardial infarction, thrombophlebitis, or venous thrombosis.\n7. Participants diagnosed with disseminated intravascular coagulation at screening (Visit 1).\n8. Participants with concomitant hepatic, renal, cardiac, pulmonary, hematologic, or other diseases that, in the investigator's judgment, may affect the efficacy or safety evaluations.\n9. Participants with current or prior lipid metabolism disorders at screening (Visit 1), such as hyperlipidemia or diabetic hyperlipidemia, or participants who require cautious administration of lipid nutritional products. However, participants whose condition is adequately controlled with medication may be enrolled at the investigator's discretion.\n10. Participants with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n11. Participants with a history of hypersensitivity to soybean, peanut, or soybean oil.\n12. Participants with a history of hypersensitivity to any component of the investigational products, such as tartrazine.\n13. Participants with clinically significant psychiatric disease at screening (Visit 1).\n14. Participants who meet any other exclusion criteria related to prior or concomitant medications specified in the protocol.","ALL","19 Years","75 Years",{"count":20,"type":21},470,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This Phase 4, multicenter, randomized, double-blind, active-controlled, non-inferiority study aims to evaluate the non-inferiority of Stoem Tab. compared to Stillen Tab. (Dong-A ST Co., Ltd.) in patients with acute or chronic gastritis. Participants will receive either Stoem Tab. or Stillen Tab. for 2 weeks. The primary outcome is the effective rate of gastric mucosal erosion at Week 2, assessed by upper gastrointestinal endoscopy and evaluated by an independent reviewer, defined as the proportion of participants achieving at least a 50% improvement in erosion score compared to baseline.",[27,28,29],"Gastritis","Acute Gastritis","Chronic Gastritis","NOT_YET_RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":21},"2026-06",{"date":38,"type":21},"2028-02",{"name":40,"class":41},"Mather's Pharm. Co., Ltd.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100602923","relationship-between-diet-and-gastritis-100602923","NCT07129824","Relationship Between Diet and Gastritis","Relationship Between Eating Habits, Food Preferences and Symptoms in Chronic Gastritis Patients","Inclusion Criteria:\n\n* • Adults aged 18 years or above\n\n  * All consecutive patients with gastrointestinal symptoms for a week or longer.\n\nExclusion Criteria:\n\n* Subjects who reported having other digestive system diseases such as peptic ulcer, pancreatitis, hepatitis, and cirrhosis\n* Serious heart, brain, liver, kidney, or hematopoietic system dysfunction or other serious diseases\n* Severe mental illness (such as schizophrenia, depression, and anxiety)\n* Food or drug allergies, pregnancy, or breastfeeding\n* Symptoms that occurred after taking prescription or over-the-counter drugs, especially aspirin or other pain relievers.","18 Years",{"count":51,"type":21},246,"OBSERVATIONAL","Chronic gastritis (CG) is a prevalent and persistent inflammatory condition that affects the gastric mucosa, carrying a significant global burden. Although CG may remain asymptomatic in some cases, many patients experience gastrointestinal (GI) symptoms such as epigastric pain, bloating, nausea, vomiting, and appetite loss.\n\nDiet plays a crucial role in both the development and progression of CG. there is a significant relationship between dietary behaviors, GI symptoms, and quality of life (QoL) in CG patients. Poor dietary habits have been associated with increased symptom severity, while healthier eating behaviors correlate with better physical and mental well-being.\n\nMost research has focused on dietary risk factors in gastric cancer patients, with limited studies exploring their impact on CG and its symptoms. Furthermore, while nutritional adjustments are frequently recommended in clinical practices such as reducing coffee and alcohol intake and avoiding heavy smoking, there is a lack of comprehensive studies evaluating the relationship between eating habits, food preferences, and symptom severity in CG patients",[29],"2025-08-16",{"date":57,"type":34},"2025-08-19",{"date":59,"type":21},"2025-08",{"date":61,"type":21},"2026-08",{"name":63,"class":64},"Sohag University","OTHER",1]